This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder: A Randomized, Double-Blind Comparison With Sertraline

Siegfried Kasper, MD, PhD; Göran Hajak, MD; Katharina Wulff, PhD; Witte J. G. Hoogendijk, MD, PhD; Angel Luis Montejo, MD, PhD; Enrico Smeraldi, MD; Janusz K. Rybakowski, MD; Maria-Antonia Quera-Salva, MD; Anna M. Wirz-Justice, PhD; Françoise Picarel-Blanchot, PhD; and Franck J. Baylé, MD

Published: February 15, 2010

Article Abstract

Objective: This study evaluates the efficacy of agomelatine, the first antidepressant to be an agonist at MT1/MT2 receptors and an antagonist at 5-HT2C receptors, versus sertraline with regard to the amplitude of the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder (MDD).

Method: Outpatients with DSM-IV-TR-defined MDD received either agomelatine 25 to 50 mg (n’ ‰=’ ‰154) or sertraline 50 to 100 mg (n’ ‰=’ ‰159) during a 6-week, randomized, double-blind treatment period. The study was conducted from 2005 to 2006. The main outcome measure was the relative amplitude of the individual rest-activity cycles, expressed as change from baseline to week 6 and collected from continuous records using wrist actigraphy and sleep logs. Secondary outcome measures were sleep efficiency and sleep latency, both derived from actigraphy, and efficacy on depression symptoms (17-Item Hamilton Depression Rating Scale total score and Clinical Global Impressions scale scores) and anxiety symptoms (Hamilton Anxiety Rating Scale total score and subscores).

Results: A significant difference in favor of agomelatine compared to sertraline on the relative amplitude of the circadian rest-activity cycle was observed at the end of the first week (P’ ‰=’ ‰.01). In parallel, a significant improvement of sleep latency (P’ ‰<‘ ‰.001) and sleep efficiency (P’ ‰<‘ ‰.001) from week 1 to week 6 was observed with agomelatine as compared to sertraline. Over the 6-week treatment period, depressive symptoms improved significantly more with agomelatine than with sertraline (P’ ‰<‘ ‰.05), as did anxiety symptoms (P’ ‰<‘ ‰.05).

Conclusions: The favorable effect of agomelatine on the relative amplitude of the circadian rest-activity/sleep-wake cycle in depressed patients at week 1 reflects early improvement in sleep and daytime functioning. Higher efficacy results were observed with agomelatine as compared to sertraline on both depressive and anxiety symptoms over the 6-week treatment period, together with a good tolerability profile. These findings indicate that agomelatine offers promising benefits for MDD patients.

Trial Registration: www.isrctn.org: ISRCTN49376288

Volume: 71

Quick Links: Neurologic and Neurocognitive , Neurology

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References